KALRAY
27.6.2022 18:02:09 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris : ALKAL) (Paris:ALKAL), a leading provider in the new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, is delighted to announce the first outcome of the synergetic combination of its DPU (“Data Processing Unit”) processor-based acceleration card K200-LP™ with newly acquired software-defined storage and data management solutions provider pixitmedia1 , a division of Arcapix Holdings Ltd dedicated to the Media & Entertainment markets. The launch of this new joint product comes just months after Kalray's acquisition of Arcapix Holdings Ltd and the new product will be showcased at Flash Memory Summit (USA) in August.
KALRAY’S ACCELERATION CARDS AND DPUs AT THE HEART OF AWARDED PIXITMEDIA’S SOFTWARE-DEFINED STORAGE AND DATA MANAGEMENT SOLUTIONS
Media & Entertainment customers are amongst the most demanding in terms of data storage and data management. The award winning pixstor and ngenea products are deployed by industry leading film studios, broadcasters, postproduction houses and VFX studios, all of whom derive value from the way in which pixitmedia puts the creative user in control of their data. Guaranteed performance, security compliance and flexibility in choice of deployment in a Hybrid, Multi-Cloud world are all a given, but it’s the smart integration with the customer’s workflow and creative pipeline management tools that elevates pixitmedia’s storage credentials.
Just a few months after Kalray’s acquisition of Arcapix Holdings Ltd, Kalray and pixitmedia have combined their technologies to offer a new version of pixstor and ngenea capable of leveraging the Kalray K200-LP™ Smart Storage Acceleration card. This combination of software and hardware offers new perspectives in terms of performance, power consumption, flexibility and, ease of use for pixitmedia’s customers in the Media & Entertainment industry.
KALRAY'S K200-LP™ DEVELOPED FOR HIGH PERFORMANCE STORAGE AND NEXT GENERATION OF DATA MANAGEMENT SOLUTIONS
K200-LP™ is the perfect solution for storage appliance makers and cloud service providers, to build their next generation of storage appliances in terms of performance per Watt per dollar.
Leveraging Kalray’s MPPA® DPU, a new generation of high performance processors tailored to process data-intensive applications, the K200-LP™ Smart Storage Accelerator cards can be programmed to accelerate rich and demanding data services.
Media & Entertainment applications require highly efficient storage and data management solutions while offering a unified, easy to use, collaborative environment for the content creators. In this context, the K200-LP™ card offers new opportunities to improve each step within the typical content workflow .
“With the K200-LP™ , we’re able to both consolidate and turbo-charge many of our existing storage-related functions and features that will help us offer even more efficient solutions to our customers. We look forward to exploiting the full power of our MPPA® DPU-based acceleration cards in the future within pixstor and ngenea, be it for accelerating our ability to help customers realize the full value of their existing content with machine learning in pixstor, or reducing the time it takes to shares assets globally with ngenea ”, said Barry Evans, Kalray Storage Business CTO and co-founder of Pixitmedia.
The K200-LP™ Smart Storage Accelerator card as well as Pixitmedia DPU-empowered solution will be showcased at Flash Memory Summit, booth #940, from August 2 to 4, 2022, at Santa Clara Convention Center, CA, USA.
ACCELERATING THE MARKET PENETRATION OF KALRAY’S ACCELERATION CARDS
One of the acquisition goals of Arcapix Holdings Ltd, of which pixitmedia is part, by Kalray was to increase growth opportunities, accelerate the commercialization of its technology and products, and leverage cross-selling opportunities. pixitmedia now gives access to new markets opportunities for Kalray, including one of the most demanding and exciting data-intensive industries – Media & Entertainment.
The integration of Kalray’s Cards into pixitmedia’s servers is an important milestone and will contribute to accelerate Kalray’s time-to-market on this specific market.
Eric Baissus, President and CEO of Kalray said: “The synergy with Arcapix is now a reality that customers can experience! We are proud to have a combined solution ready just a few months after the acquisition. It shows both the complementarity of our offering and the unique collaborative mindset that we managed to instill within our company .”
About KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
1 pixitmedia is the dedicated division for Media & Entertainment markets of Arcapix Holdings Ltd, acquired by Kalray. See press release on March 3, 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005583/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom